Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19

Abstract

Early treatment (i.e., soon after the onset of Covid-19 symptoms) with monoclonal antibodies that target the SARS-CoV-2 spike protein reduces the risks of Covid-19–related hospitalization and death.1-3 Yet, despite the success of these interventions, in response to continued pressure from human immune responses, the SARS-CoV-2 spike protein has evolved to evade almost all available monoclonal antibody–based drugs.4 In this issue of the Journal, Levin et al.5 report on the use of AZD7442 (tixagevimab–cilgavimab) for the prevention of Covid-19. Tixagevimab and cilgavimab are monoclonal antibodies that target the SARS-CoV-2 spike protein. Both were derived from B cells obtained from persons infected . . .